Published in J Immunol on August 01, 1975
Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med (1982) 8.74
Lymphocyte cytotoxicity to autologous hepatocytes in HBsAg-negative chronic active hepatitis. Clin Exp Immunol (1979) 1.47
Loss of circulating T lymphocytes with normal levels of B and 'null' lymphocytes in Thai adults with malaria. Clin Exp Immunol (1979) 1.45
Absence of allogeneic restriction in human T-cell-mediated cytotoxicity to Epstein-Barr virus-infected target cells. Demonstration of an HLA-linked control at the effector level. J Exp Med (1979) 1.27
In vitro induction of cytotoxic effector cells with spontaneous killer cell specificity. J Exp Med (1978) 1.19
Lymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma. Br J Cancer (1977) 1.18
Immune response in humans after vaccination with vaccinia virus: generation of a virus-specific cytotoxic activity by human peripheral lymphocytes. J Exp Med (1977) 1.18
Spontaneous cell-mediated cytotoxicity in humans. Distribution and characterization of the effector cell. Clin Exp Immunol (1978) 1.15
Natural cytotoxic reactivity of human lymphocyte subpopulations. Immunology (1979) 1.07
In vitro cell-mediated cytotoxicity in primary biliary cirrhosis and chronic hepatitis. Dysfunction of spontaneous cell-mediated cytotoxicity in primary biliary cirrhosis. J Clin Invest (1977) 1.06
The repertoire of HLA-Cw-specific NK cell receptors CD158 a/b (EB6 and GL183) in individuals with different HLA phenotypes. Immunology (1997) 0.97
Isolation of spontaneous and interferon inducible natural killer like cells from human colonic mucosa: lysis of lymphoid and autologous epithelial target cells. Clin Exp Immunol (1983) 0.94
Inhibition of spontaneous but not antibody-dependent cell-mediated cytotoxicity by simple sugars: evidence that endogenous lectins may mediate spontaneous cell-mediated cytotoxicity. Immunology (1981) 0.92
A CD8α(-) subpopulation of macaque circulatory natural killer cells can mediate both antibody-dependent and antibody-independent cytotoxic activities. Immunology (2011) 0.91
Kinetics of peripheral blood leukocyte alterations in Thai children with dengue hemorrhagic fever. Infect Immun (1980) 0.88
Further evidence that antibody-dependent and spontaneous cell-mediated cytotoxicity are mediated by different processes or cell types. Immunology (1980) 0.88
Medullasin enhances human natural killer cell activity. J Clin Invest (1982) 0.87
Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma. A sequential study over 28 days. II. Changes in non-specific (NK, K and T cell) lymphocytoxicity and delayed hypersensitivity skin reactions. Clin Exp Immunol (1979) 0.87
Spontaneous and lectin-dependent cellular cytotoxicity by lymphocyte subpopulations against cell lines susceptible or resistant to spontaneous cytotoxicity. Clin Exp Immunol (1978) 0.86
Antibody-dependent cellular cytotoxicity to human colon-tumour cells. I. Lack of tumour specificity in a population study. Br J Cancer (1979) 0.84
Inhibition of lymphocyte cytotoxicity in chronic active hepatitis. Clin Exp Immunol (1978) 0.81
Lymphocyte-mediated cytotoxicity in humans during revaccination with vaccinia virus. Infect Immun (1978) 0.80
Induction of activated killer cells from human lymphocytes by medullasin (a serine protease in bone marrow cells). Immunology (1992) 0.80
Effect of vitamin E on cell-mediated immune responses and serum corticosterone in young and maturing mice. Immunology (1981) 0.78
Antibody-dependent and spontaneous lympholysis in urologic cancer patients. Br J Cancer (1979) 0.77
Influence of continuous-flow blood separator leucophoresis on in vitro functions of human lymphocytes. Clin Exp Immunol (1978) 0.75
Characterization of cell-mediated cytolytic mechanisms against human transitional cell carcinoma line, 253J. Immunology (1980) 0.75
Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet (2005) 3.97
Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum (2004) 3.46
Stimulation of lymphocytes by autologous leukaemic cells in acute leukaemia. Nature (1969) 2.75
Antibody-induced redistribution of HL-A antigens at the cell surface. Eur J Immunol (1972) 2.58
Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet (2004) 2.55
Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes. Science (1992) 2.41
The structure of a human type III Fcgamma receptor in complex with Fc. J Biol Chem (2001) 2.33
Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res (1999) 2.23
Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol (2003) 2.20
Theiler's virus infection of 129Sv mice that lack the interferon alpha/beta or interferon gamma receptors. J Exp Med (1995) 2.19
The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc gamma RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity (1995) 2.12
Theiler's virus infection of beta 2-microglobulin-deficient mice. J Virol (1993) 2.04
Demyelinating lesions due to Theiler's virus are associated with ongoing central nervous system infection. J Virol (1986) 1.95
Genetic mapping of the ability of Theiler's virus to persist and demyelinate. J Virol (1990) 1.82
Independence of H-2K and H-2D antigenic determinants on the surface of mouse lymphocytes. J Exp Med (1973) 1.76
Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation. Lancet (1997) 1.76
Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature. Ann Rheum Dis (2003) 1.75
Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet (1993) 1.72
Prognostic value of intratumoral interferon gamma messenger RNA expression in invasive cervical carcinomas. J Natl Cancer Inst (1998) 1.71
Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J Clin Invest (1995) 1.70
Brain glucose utilization in systemic lupus erythematosus with neuropsychiatric symptoms: a controlled positron emission tomography study. Eur J Nucl Med (1997) 1.66
Molecular cloning of the complete genome of Theiler's virus, strain DA, and production of infectious transcripts. Microb Pathog (1989) 1.62
A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease. Immunobiology (1990) 1.60
Tyrosine-containing motif that transduces cell activation signals also determines internalization and antigen presentation via type III receptors for IgG. Nature (1992) 1.60
The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet (2009) 1.59
Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer. Lancet (2001) 1.58
Successful treatment of gastrointestinal vasculitis due to systemic lupus erythematosus with intravenous pulse cyclophosphamide: a clinical case report and review of the literature. Br J Rheumatol (1998) 1.56
Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev (2011) 1.55
Membrane immunofluorescence reactions of Burkitt lymphoma cells from biopsy specimens and tissue cultures. J Natl Cancer Inst (1967) 1.52
Independence of HL-A antigens and immunoglobulin determinants on the surface of human lymphoid cells. Eur J Immunol (1972) 1.52
Giant cell arteritis is more prevalent in urban than in rural populations: results of an epidemiological study of primary systemic vasculitides in Germany. Rheumatology (Oxford) (2000) 1.52
Transient hypogammaglobulinemia of infancy: Five new cases, review of the literature and redefinition. Acta Paediatr Scand (1989) 1.51
Of worms and men: an evolutionary perspective on the fibroblast growth factor (FGF) and FGF receptor families. J Mol Evol (1997) 1.51
Relationship between the EBV-associated membrane antigen on Burkitt lymphoma cells and the viral envelope, demonstrated by immunoferritin labelling. Int J Cancer (1971) 1.50
Characterization and function of T cell Fc gamma receptor. Immunol Rev (1981) 1.50
Magnetic resonance imaging (MRI) for detection of active sacroiliitis--a prospective study comparing conventional radiography, scintigraphy, and contrast enhanced MRI. J Rheumatol (1996) 1.49
Differential modulation of stimulatory and inhibitory Fc gamma receptors on human monocytes by Th1 and Th2 cytokines. J Immunol (2001) 1.48
T-cell hybrids bear Fcgamma receptors and secrete suppressor immunoglobulin binding factor. Nature (1979) 1.47
Severe combined immunodeficiency due to defective binding of the nuclear factor of activated T cells in T lymphocytes of two male siblings. Eur J Immunol (1996) 1.47
Type II collagen-specific human T cell lines established from healthy donors. Eur J Immunol (1990) 1.47
Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clin Immunol (2011) 1.44
Quantification by flow cytofluorimetry of HLA class I molecules at the surface of murine cells transformed by cloned HLA genes. J Immunol Methods (1983) 1.39
Intravascular coagulation necrosis of the skin associated with cryofibrinogenemia, diabetes mellitus, and cardiolipin autoantibodies. J Am Acad Dermatol (1991) 1.39
Posttraumatic reflex sympathetic dystrophy anteceding inverse psoriasis and psoriatic arthritis. J Rheumatol (1995) 1.39
Suppression of in vitro antibody synthesis by immunoglobulin-binding factor. J Exp Med (1975) 1.37
Highly resolved chemical imaging of living cells by using synchrotron infrared microspectrometry. Proc Natl Acad Sci U S A (1998) 1.36
Tumorigenicity of human malignant melanocytes in nude mice in relation to their differentiation in vitro. J Natl Cancer Inst (1980) 1.36
FHL-1/reconectin and factor H: two human complement regulators which are encoded by the same gene are differently expressed and regulated. Mol Immunol (2000) 1.33
The duration of nuclear residence of NFAT determines the pattern of cytokine expression in human SCID T cells. J Immunol (2000) 1.32
Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis (2004) 1.30
Theiler's virus replication in brain macrophages cultured in vitro. J Virol (1992) 1.30
Melanoma and use of sunscreens: an Eortc case-control study in Germany, Belgium and France. The EORTC Melanoma Cooperative Group. Int J Cancer (1995) 1.30
Fc epsilon receptor I-associated lyn-dependent phosphorylation of Fc gamma receptor IIB during negative regulation of mast cell activation. J Immunol (1998) 1.28
Cutaneous malignant melanoma and exposure to sunlamps or sunbeds: an EORTC multicenter case-control study in Belgium, France and Germany. EORTC Melanoma Cooperative Group. Int J Cancer (1994) 1.27
Determinants of persistence and demyelination of the DA strain of Theiler's virus are found only in the VP1 gene. J Virol (1991) 1.27
Absence of allogeneic restriction in human T-cell-mediated cytotoxicity to Epstein-Barr virus-infected target cells. Demonstration of an HLA-linked control at the effector level. J Exp Med (1979) 1.27
The DiGeorge syndrome. I. Clinical evaluation and course of partial and complete forms of the syndrome. Eur J Pediatr (1988) 1.27
Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function. Int J Cancer (1995) 1.25
Epitopic analysis of detergent-solubilized HLA molecules by solid-phase radioimmunoassay. J Immunol Methods (1982) 1.25
Role of B cell receptor Ig alpha and Ig beta subunits in MHC class II-restricted antigen presentation. Immunity (1995) 1.25
Rapid catabolism of 5-fluorouracil in freshly isolated rat hepatocytes as analyzed by high performance liquid chromatography. J Biol Chem (1982) 1.25
GARP: a key receptor controlling FOXP3 in human regulatory T cells. J Cell Mol Med (2009) 1.25
Enzymatic reduction of chromate: comparative studies using sulfate-reducing bacteria. Key role of polyheme cytochromes c and hydrogenases. Appl Microbiol Biotechnol (2001) 1.23
Overexpression of zinc-finger transcription factor Z-225/Egr-1 in synoviocytes from rheumatoid arthritis patients. J Immunol (1994) 1.23
Role of associated gamma-chain in tyrosine kinase activation via murine Fc gamma RIII. EMBO J (1992) 1.20
Spontaneous cytotoxicity (SCMC) of normal human lymphocytes against a human melanoma cell line: a phenomenon due to a lymphotoxin-like mediator. J Immunol (1976) 1.20
PAF-acether-induced plasma exudation in rat skin is independent of platelets and neutrophils. Microcirc Endothelium Lymphatics (1984) 1.19
Immunological and functional characteristics of peripheral blood and synovial fluid lymphocytes from patients with rheumatoid arthritis. Scand J Immunol (1978) 1.19
Isotype regulation of antibody production: T-cell hybrids can be selectively induced to produce IgG1 and IgG2 subclass-specific suppressive immunoglobulin-binding factors. Proc Natl Acad Sci U S A (1983) 1.19
Immunophenotypical alterations in a subset of patients with common variable immunodeficiency (CVID). Clin Exp Immunol (1992) 1.19
3-Alkanoyl-5-hydroxymethyl tetronic acid homologues and resistomycin: new inhibitors of HIV-1 protease. I. Fermentation, isolation and biological activity. J Antibiot (Tokyo) (1994) 1.19
Differentiation between early and late membrane antigen on human lymphoblastoid cell lines infected with Epstein-Barr virus. I. Immunofluorescence. J Natl Cancer Inst (1974) 1.18
Immunoferritin study of the distribution of HL-A antigens on human blood cells. J Immunol (1971) 1.17
Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant (2008) 1.17
Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors. Am J Pathol (1998) 1.15
Immunosuppressive treatment of chronic periaortitis: a retrospective study of 20 patients with chronic periaortitis and a review of the literature. Ann Rheum Dis (2005) 1.15
[Ultrastructure of the wall of Neisseria meningitidis]. Ann Inst Pasteur (Paris) (1967) 1.15
Suppression of mitogen-induced peripheral B cell differentiation by soluble Fc gamma receptors released from lymphocytes. Eur J Immunol (1980) 1.14
A 55,000 Mr surface antigen on activated human T lymphocytes defined by a monoclonal antibody. Hum Immunol (1983) 1.14
Mycoplasma contamination in human tumor cell lines: effect on interferon induction and susceptibility to natural killing. J Immunol (1981) 1.13
Chemical imaging of nucleic acids, proteins and lipids of a single living cell. Application of synchrotron infrared microspectrometry in cell biology. Cell Mol Biol (Noisy-le-grand) (1998) 1.13
Activated CD4+ and CD8+ T-cell subsets in Wegener's granulomatosis. Rheumatol Int (1995) 1.13
Difficulties encountered in the application of Clark classification and the Breslow thickness measurement in cutaneous malignant melanoma. Int J Cancer (1980) 1.12
Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer (1994) 1.12
Modulation of interleukin-18 expression in human colon carcinoma: consequences for tumor immune surveillance. Int J Cancer (1999) 1.11
Macrophage inflammatory protein-1alpha is induced by human immunodeficiency virus infection of monocyte-derived macrophages. Blood (1996) 1.11
Distinct epitopes of Ik gene products identified by monoclonal antibodies. Eur J Immunol (1980) 1.11
Role of the humoral immune response in resistance to Theiler's virus infection. J Virol (1991) 1.11
The basic domain of the lentiviral Tat protein is responsible for damages in mouse brain: involvement of cytokines. Virology (1994) 1.10
Major histocompatibility complex haplotypes and complement C4 alleles in systemic lupus erythematosus. Results of a multicenter study. J Clin Invest (1992) 1.10
T cell hybridomas coexpressing Fc receptors (FcR) for different isotypes. II. IgA-induced formation of suppressive IgA binding factor(s) by a murine T hybridoma bearing Fc gamma R and Fc alpha R. J Immunol (1983) 1.10
Immunoglobulin-binding factor present on and produced by thymus-processed lymphocytes (T cells). Cell Immunol (1974) 1.10
The role of the Fc receptor (FcR) of thymus-derived lymphocytes. II. Presence of FcR on suppressor cells and direct involvement in suppression. Eur J Immunol (1977) 1.09
Diagnosis and monitoring of central nervous system involvement in systemic lupus erythematosus: value of F-18 fluorodeoxyglucose PET. Ann Rheum Dis (2000) 1.08
Long-lasting insomnia induced by preoptic neuron lesions and its transient reversal by muscimol injection into the posterior hypothalamus in the cat. Neuroscience (1989) 1.08
A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunol Immunother (2010) 1.08
Interferon enhances the expression of Fc gamma receptors. J Immunol (1980) 1.08